teriparatide + Placebo

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Lumbar Spondylosis

Conditions

Lumbar Spondylosis, Lumbar Spondylolisthesis, Adult Degenerative Lumbar Scoliosis

Trial Timeline

Aug 1, 2011 → Dec 1, 2016

NCT ID

NCT01292252

About teriparatide + Placebo

teriparatide + Placebo is a approved stage product being developed by Eli Lilly for Lumbar Spondylosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01292252. Target conditions include Lumbar Spondylosis, Lumbar Spondylolisthesis, Adult Degenerative Lumbar Scoliosis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03072147	Phase 2	Completed	May 1, 2017	Sep 30, 2022	Knee Osteoarthritis
NCT01473589	Phase 3	Completed	Feb 1, 2012	Dec 1, 2013	Femur Neck Fracture
NCT01473602	Phase 3	Completed	Jan 1, 2012	Nov 1, 2013	Femur Neck Fracture
NCT01292252	Approved	Completed	Aug 1, 2011	Dec 1, 2016	Lumbar Spondylosis
NCT01279187	Phase 2	Terminated	Feb 1, 2011	Nov 1, 2015	Implant
NCT01173081	Approved	UNKNOWN	Jul 1, 2010	Apr 1, 2014	Fractures
NCT00433160	Phase 3	Completed	Jan 1, 2007	Sep 1, 2009	Osteoporosis
NCT00190944	Phase 2	Completed	Dec 1, 2004	Jun 1, 2007	Colles' Fracture

Competing Products

4 competing products in Lumbar Spondylosis

See all competitors

Product	Company	Stage	Hype Score
Pregabalin + Diphenhydramine	Pfizer	Approved	84
BG00010 IV + BG00010 SC + Placebo IV + Placebo SC	Biogen	Phase 1	30
BG00010 + Placebo	Biogen	Phase 2	49
BRTX-100 + Saline	BioRestorative Therapies	Phase 2	44

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved